Stockscreener 앱 받기
12.83
2.51%
-0.33
시간 외 거래:
12.83
전일 마감가:
$13.16
열려 있는:
$13.13
하루 거래량:
314.79K
Relative Volume:
1.52
시가총액:
$373.68M
수익:
$69.21M
순이익/손실:
$-61.98M
주가수익비율:
-4.9447
EPS:
-2.5947
순현금흐름:
$-9.61M
1주 성능:
-7.10%
1개월 성능:
-6.62%
6개월 성능:
-7.43%
1년 성능:
+60.38%
1일 변동 폭
$12.59
$13.32
1주일 범위
$12.59
$13.98
52주 변동 폭
$7.05
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
Compare ENTA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
12.83 | 383.29M | 69.21M | -61.98M | -9.61M | -2.5947 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Rodman & Renshaw | Buy |
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Enanta Pharmaceuticals Inc (NASDAQ: ENTA) Share Price, ENTA Stock News, ENTA Share Price & Updates - Kalkine
Enanta Pharmaceuticals (ENTA) Stock Faces Revenue Slip And Wider Losses - Sahm
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Enanta Pharma reports $19.5 million Q3 loss, advances RSV pipeline - scanx.trade
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates - NewsBreak: Local News & Alerts
Is Enanta Pharmaceuticals (ENTA) Overvalued After Q3 Earnings Mi - GuruFocus
Enanta Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Enanta Pharma misses Q3 estimates on lower royalty revenue By Investing.com - Investing.com Canada
Enanta Fiscal Q3 2026 Earnings: Higher Royalty-Related Interest Expense Widens Net Loss - TradingKey
Enanta Pharma misses Q3 estimates on lower royalty revenue - Investing.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Misses Expectations By $0.16 EPS - marketbeat.com
Enanta Pharmaceuticals reports Q3 loss; revenue $14.4M, cash and securities $211.5M - TradingView
Enanta Pharma On Track to File IND for EPS-3903, an Oral, Once-Daily STAT6 Inhibitor and to Select MRGPRX2 Development Candidate, in 2H >ENTA - Moomoo
Enanta Pharmaceuticals: Fiscal Q3 Earnings Snapshot - AOL.com
Press Release: Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2026 - Moomoo
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Enanta Pharmaceuticals (ENTA) Climbs 3.2% as Shares Test Key Resistance at $14.46Market Profile - dars.gov.et
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(ENTA) Risk Channels and Responsive Allocation - Stock Traders Daily
Enanta Pharmaceuticals (ENTA) Expected to Post Quarterly Earnings on Monday - MarketBeat
Enanta Pharmaceuticals Inc (ENTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ENTA|Enanta Pharmaceuticals Inc|Price:12.780|Chg%:-0.170 - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enanta Pharmaceuticals Inc (ENTA) Shareholder Structure: Major Shareholders & Institutional Holdings - tradingkey.com
Enanta Pharmaceuticals Inc (ENTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
ENTA|Enanta Pharmaceuticals Inc|Price:12.730|Chg%:-0.050 - TradingKey
Enanta Pharmaceuticals (ENTA) Slides to $12.78 as Selling Pressure PersistsKeltner Channel - dars.gov.et
Enanta Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals (ENTA) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Enanta Pharmaceuticals Inc (ENTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enanta Pharmaceuticals (9EP) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Enanta Was First to File. Pfizer Still Won. The Difference Was One Digit. - JD Supra
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta v. Pfizer is Not About a Typo: It is About Possession of the Invention - IPWatchdog.com
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – BX:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
(ENTA) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – SWB:9EP - TradingView
Enterprise value to EBITDA forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – DUS:9EP - TradingView
Enterprise value to EBIT forward of Enanta Pharmaceuticals, Inc. – GETTEX:9EP - TradingView
Enanta Pharmaceuticals (ENTA) Q2 2026 Earnings: Narrower Loss Surprises Amid Steady Pipeline Progress - dars.gov.et
Enanta Pharmaceuticals outlines its antiviral pipeline. Focus on long-term opportunities for ENTA st - ad-hoc-news.de
Enanta Pharmaceuticals Establishes Flexible At-The-Market Offering - The Globe and Mail
Liquidity Mapping Around (ENTA) Price Events - Stock Traders Daily
Enanta Enters $75 Million At-the-Market Stock Offering Agreement - Moomoo
Federal Circuit Rules Written Description Standard Governs Patent Priority In Enanta Pharmaceuticals v. Pfizer (PFE) - londoninsider.co.uk
Price to sales forward of Enanta Pharmaceuticals, Inc. – NASDAQ:ENTA - TradingView
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2500 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals, Inc.(NasdaqGS: ENTA) added to Russell 2000 Growth Benchmark - marketscreener.com
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Enanta Pharmaceuticals Inc 주식 (ENTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Trout Harry R. III | See Remarks |
Dec 05 '25 |
Sale |
14.23 |
542 |
7,713 |
16,348 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 05 '25 |
Sale |
14.23 |
798 |
11,356 |
21,792 |
| Luu Brendan | Chief Business Officer |
Dec 05 '25 |
Sale |
14.23 |
1,394 |
19,837 |
38,329 |
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 05 '25 |
Sale |
14.23 |
2,106 |
29,968 |
30,620 |
| Or Yat Sun | Chief Scientific Officer |
Dec 05 '25 |
Sale |
14.23 |
2,390 |
34,010 |
371,392 |
| Luly Jay R. | President and CEO |
Dec 05 '25 |
Sale |
14.23 |
4,743 |
67,493 |
858,026 |
1.80%
1.77%
자본화:
|
볼륨(24시간):